Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI)
Industry: Healthcare

OFF LIST - 1044 consecutive market days: OFF LIST as of 04/12/2012 Through 11/14/2016

Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival. It is developing NurOwn for various neurodegenerative diseases, including its lead indication, which is in Phase III clinical trial for the treatment of amyotrophic lateral sclerosis, as well as in Phase II for the treatment of multiple sclerosis, and preclinical trial for Parkinson's disease, Huntington's disease, and autism spectrum disorder. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was founded in 2000 and is headquartered in New York, New York.

Current Quote*
Last: $4.020
Change: -0.110
Book: $273.333
Volume: 41,647

As Of: 07/19 13:14 ET
*Quotes delayed by 20min.

Graphs for BCLI


3 Month Graph


6 Month Graph


1 Year Graph